Effect of Rivaroxaban on Coagulation Parameters- an ex Vivo Study
Differences in Laboratory Coagulation Parameters
|Study Design:||Observational Model: Cohort
Time Perspective: Retrospective
|Study Start Date:||September 2009|
|Study Completion Date:||April 2011|
|Primary Completion Date:||June 2010 (Final data collection date for primary outcome measure)|
To validate the effects of Rivaroxaban on coagulation parameters plasma samples of patients after hip or knee replacement surgery treated with Rivaroxaban 10 mg/d are investigated.
Plasma samples are obtained by blood collection before, after 2 hours and after 12 hours after Rivaroxaban dosing in steady state (on 3rd - 5th day).
Several techniques, including clot-based tests, chromogenic assays and ELISA´s are used for coagulation assays in our coagulation laboratory Frankfurt/Main. The influence of Rivaroxaban on different coagulation assays should be investigated in our coagulation laboratory.
Please refer to this study by its ClinicalTrials.gov identifier: NCT00986635
|University Hospital Frankfurt|
|Frankfurt am Main, Germany, 60590|
|Principal Investigator:||Helen Mani, PhD||Johann Wolfgang Goethe University Hospital Frankfurt/Main Germany|